The recommended dose of ALTUVIIIO as a routine prophylaxis for adults and children is 50 IU/kg, administered once weekly.1
0 IU
* Vials shown are only representational.
ALTUVIIIO delivers on-demand bleed control with a recommended single dose of 50 IU/kg for all types of bleeding episodes.1
0 IU
* For minor and moderate bleeding episodes occurring within 2 to 3 days after a prophylactic dose, a lower dose of 30 IU/kg dose may be used.
Minor and moderate bleeding | For minor and moderate bleeding episodes occurring within 2 to 3 days after a prophylactic dose, a lower dose of 30 IU/kg dose may be used. Additional doses of 30 IU/kg or 50 IU/kg every 2 to 3 days may be considered. |
Major bleeding | Additional doses of 30 IU/kg or 50 IU/kg every 2 to 3 days may be considered. |
For resumption of prophylaxis (if applicable) after treatment of a major bleed | It is recommended to allow an interval of at least 72 hours between the last on-demand dose for treatment of a bleed and resuming prophylaxis dosing. Thereafter, prophylaxis can be continued as usual on the patient’s regular schedule. |
Examples of minor and moderate bleeding episodes include: Uncomplicated joint bleeds, minor muscular bleeds, mucosal or subcutaneous bleeds. | Examples of major bleeding episodes include: Intracranial, retroperitoneal, iliopsoas and neck bleeds, muscle bleeds with compartment syndrome, and bleeds associated with a significant decrease in the hemoglobin level. |
Your independent medical consideration should be given to maintaining Factor VIII activity at or above the target range.
ALTUVIIIO delivers perioperative bleed management with a recommended single dose of 50 IU/kg.1
0 IU
0 IU
Major surgery: Additional doses of 30 IU/kg or 50 IU/kg every 2 to 3 days may be administered as clinically needed for perioperative management. Examples of major surgery include intracranial, intra-abdominal, joint replacement surgery, or complicated dental procedures.1
The calculator information is provided as a guide for dosing ALTUVIIIO for prophylaxis, the control of bleeding episodes, and perioperative management. Your independent medical consideration should be given to maintaining Factor VIII activity at or above the target range.
* Copay Program not valid for patients utilizing Medicare, Medicaid, VA, DoD, TRICARE®, or similar federal or state programs including any state pharmaceutical assistance programs to pay in part or in full for their prescriptions. Savings may vary depending on patients’ out of pocket costs. Free Trial Plus valid only for a patient’s first prescriptions and it is limited to one use per patient per product for their lifetime. Free products dispensed through the Free Trial Plus or Factor Access Programs shall not be submitted to any third-party payer, public or private (e.g. private insurance, Medicaid, Medicare, VA, DoD, TRICARE®, or similar federal or state programs) for reimbursement. All Programs not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Programs at any time without notice. Program details provided upon registration.
† Terms and conditions apply.
IU=international unit.
Reference: 1. ALTUVIIIO Prescribing Information. Bioverative Therapeutics Inc. Waltham, MA.
